Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results1 passage
• A phase 2a trial of brepocitinib for cicatricial alopecia1 passage
• Association between alopecia areata, anxiety, and depression: A systematic review and meta-analysis1 passage
• Comorbidities in alopecia areata: A systematic review and meta-analysis1 passage
• Complementary and alternative medicine for alopecia areata: A systematic review1 passage
• Effect of prenatal high-dose vitamin D on childhood atopic dermatitis is modified by maternal cotinine metabolome: A secondary analysis of a randomized clinical trial1 passage
• Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study1 passage
• Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial1 passage
• Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)1 passage
• Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study1 passage
• Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis1 passage
• Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: A randomized controlled trial1 passage
• Full Guidelines-From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis1 passage
• Guidelines of care for the management of cutaneous squamous cell carcinoma1 passage
• Guidelines of care for the primary prevention of atopic dermatitis and awareness of comorbid conditions in pediatric atopic dermatitis1 passage
• Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial1 passage
• Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities1 passage
• Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients1 passage
• Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors1 passage
• Low-dose oral minoxidil does not significantly affect blood pressure: A systematic review and meta-analysis1 passage
• North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations1 passage
• Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review1 passage
• Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial1 passage
• Skin diseases associated with Agent Orange and other organochlorine exposures1 passage
• The effect of platelet-rich plasma on female androgenetic alopecia: A randomized controlled trial1 passage
• The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis1 passage
• Treatment of androgenetic alopecia in transgender people receiving testosterone therapy with sublingual minoxidil: A randomized, double-blind, placebo-controlled clinical trial1 passage
• Treatment of pediatric alopecia areata: A systematic review1 passage